Atacicept is a novel immunomodulatory therapy that inhibits BLyS and APRIL signaling, which has been shown to reduce Ig levels in patients with autoimmune diseases, including systemic lupus erythematosus.21 This evidence concerns the gene TNFSF13 and systemic lupus erythematosus.